MUMBAI- Alkem Labs, India’s sixth largest drug maker by market share, is set to see a top management change. Vikas Gupta, who helmed the organization for close to three years as its CEO, is expected to move out in a few months, sources told ET.
Alkem did not respond to questions from ET.
Gupta had joined Alkem from rival Cipla, where he had headed the India formulations business. With a medical degree and a deep knowledge of the Indian market, Gupta has held previous stints in Glenmark and Ranbaxy.
Sources noted Gupta is being wooed by a few organizations, including a few private equity players, for a leadership role. However, this could not be confirmed. “It may or may not happen as talks are still on,” a senior executive from a rival organization said.
In a rare interview with ET recently, Vikas Gupta had said Alkem, which has a strong portfolio of anti-infective drugs like Clavam, is planning to strengthen its presence in chronic products such as cardiac care and anti-diabetes products.
He added the launch of its semaglutide brands is expected to accelerate that goal. Alkem launched its weight-loss drugs - Hepaglide, Obesema and Semasize – on March 21, the day the patent for semaglutide expired in India. The company clocked revenues close to Rs 13000 in FY2025-26, of which over 70% was contributed by the India business.
Alkem did not respond to questions from ET.
Gupta had joined Alkem from rival Cipla, where he had headed the India formulations business. With a medical degree and a deep knowledge of the Indian market, Gupta has held previous stints in Glenmark and Ranbaxy.
Sources noted Gupta is being wooed by a few organizations, including a few private equity players, for a leadership role. However, this could not be confirmed. “It may or may not happen as talks are still on,” a senior executive from a rival organization said.
In a rare interview with ET recently, Vikas Gupta had said Alkem, which has a strong portfolio of anti-infective drugs like Clavam, is planning to strengthen its presence in chronic products such as cardiac care and anti-diabetes products.
He added the launch of its semaglutide brands is expected to accelerate that goal. Alkem launched its weight-loss drugs - Hepaglide, Obesema and Semasize – on March 21, the day the patent for semaglutide expired in India. The company clocked revenues close to Rs 13000 in FY2025-26, of which over 70% was contributed by the India business.
